Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
Background We have shown previously that low‐density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL receptor–deficient mice fed a...
Guardado en:
Autores principales: | Feroz Ahmad, Robert D. Mitchell, Tom Houben, Angela Palo, Tulasi Yadati, Andrew J. Parnell, Ketan Patel, Ronit Shiri‐Sverdlov, David S. Leake |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fda9f1c4cdf04659bffbd7796e762592 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Potential Role of Electronegative High-Density Lipoprotein H5 Subfraction in RA-Related Atherosclerosis
por: Ching-Kun Chang, et al.
Publicado: (2021) -
Monocyte/High-Density Lipoprotein Ratio Predicts the Prognosis of Large Artery Atherosclerosis Ischemic Stroke
por: Youyu Li, et al.
Publicado: (2021) -
The Association of Syntax Score with Levels of Lipoprotein(a) and Inflammatory Biomarkers in Patients with Stable Coronary Artery Disease and Different Low-Density Lipoprotein Cholesterol Levels
por: Xu W, et al.
Publicado: (2020) -
Detection of Low Density Lipoprotein—Comparison of Electrochemical Immuno- and Aptasensor
por: Daria Rudewicz-Kowalczyk, et al.
Publicado: (2021) -
Efecto inmunosupresor in vitro de las lipoproteínas de baja densidad
por: González R,Margarita, et al.
Publicado: (1999)